VivoSeq
Ophthalmology

Corneal Neovascularization

10

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Corneal Neovascularization is an early-stage landscape with 10 programs across 6 companies. The most active players are Chengdu Kanghong Biotech Co., Ltd., Novartis, Roche. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

70/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chengdu Kanghong Biotech Co., Ltd.

2 programs

Phase 1Novartis logo

Novartis

1 program

Phase 1Roche logo

Roche

1 program

Phase 1Grifols Therapeutics LLC logo

Grifols Therapeutics LLC

1 program

Phase 1Regeneron logo

Regeneron

2 programs

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

69%

Small molecule

9 of 13 classified programs — the dominant modality here.

31%ALL OTHERSMonoclonal antibody215%Protein / enzyme215%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 93% of 15 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed7 · 50%
Unknown status3 · 21%
Terminated2 · 14%
Withdrawn1 · 7%
Recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT07329686·100 enrolled
The Effect of Bevacizumab on Corneal Neovascularization
Completed·IInstituto de Olhos de Goiania·Phase 4·NCT00797303·8 enrolled
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
Completed·AAsociación para Evitar la Ceguera en México·Phase 2/3·NCT00555594·18 enrolled
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
Completed·MMedical College of Hampton Roads·N/A·NCT00004430·150 enrolled
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
Completed·RReza Dana, MD·Phase 1·NCT00681889·9 enrolled
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Completed·WWalter Reed Army Medical Center·N/A·NCT00512876·24 enrolled
Topical Avastin for Treatment of Corneal Neovascularization
Completed·MMassachusetts Eye and Ear Infirmary·Phase 1·NCT00559936·24 enrolled
Treatment of Corneal Neovascularization With Topical Pazopanib
Completed·RReza Dana, MD·Phase 1/2·NCT01257750·20 enrolled
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
Terminated·RRabin Medical Center·Phase 1/2·NCT02797704·6 enrolled
Topical IL-1-Ra for Treatment of Corneal Neovascularization
Terminated·RReza Dana, MD·Phase 1/2·NCT00915590·10 enrolled
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
Withdrawn·UUniversity of Utah·Phase 1·NCT02042027
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 1·NCT04215393·39 enrolled
Bevacizumab for the Treatment of Corneal Neovascularization
Unknown status·—·Phase 2·NCT00992849·10 enrolled
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
Unknown status·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Phase 1/2·NCT05011916·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)